中国血液透析患者感染奥密克戎BA.5后的特异性体液免疫应答与XBB变异株再感染风险
研究纳入178例感染BA.5的血液透析患者(其中53例既往接种过疫苗),比较未接种与接种者的体液免疫应答,并分析XBB变异株再感染的危险因素。结果显示,加强接种者BA.5和XBB.1.16特异性抗体及中和抗体水平显著高于未接种者,但XBB.1.16特异性中和抗体水平不能预测再感染风险;低球蛋白水平和较短透析龄是XBB再感染的独立危险因素。
要点
- 加强接种的BA.5感染透析患者BA.5和XBB.1.16特异性抗体及中和抗体水平显著高于未接种者。
- 低球蛋白水平和较短血液透析时长是XBB再感染的独立危险因素。
- XBB.1.16特异性中和抗体水平低,但不能预测再感染风险。
核心结论
- BA.5感染透析患者中XBB.1.16特异性中和抗体水平虽低,但不能预测再感染风险,其他潜在危险因素需未来研究。
研究设计与样本
- 研究纳入178例感染BA.5的血液透析患者,其中53例既往接种过疫苗,比较未接种与接种者的体液免疫应答。
- 采用酶联免疫吸附法检测抗祖先株S1-IgG、抗BA.5受体结合域(RBD)-IgG和抗XBB.1.16-RBD-IgG,用假病毒中和试验测定BA.5和XBB.1.16中和抗体滴度。
- 采用单因素和多因素二元logistic回归分析识别重症感染、特异性体液免疫强度和XBB变异株再感染易感性的相关因素。
主要发现
- 完成全程或加强接种的BA.5感染透析患者抗祖先株S1-IgG水平高于未接种者,但抗BA.5-RBD-IgG和抗XBB.1.16-RBD-IgG水平低得多。
- 加强接种的BA.5感染透析患者BA.5和XBB.1.16特异性抗体及中和抗体水平显著高于未接种患者。
- 低球蛋白水平和较短血液透析时长是BA.5感染透析患者XBB再感染的独立危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, there is limited understanding of the specific humoral immune response in BA.5-infected hemodialysis patients (BA.5-CHDPs) with previous COVID-19 vaccination. Additionally, the relevant risk factors for reinfection with XBB variants in BA.5-CHDPs have yet to be elucidated. METHOD: A total of 178 BA.5-CHDPs were enrolled in this study among 53 patients who had previous vaccination. To compare hemodialysis patients in both unvaccinated and vaccinated for their immune response to the BA.5 subtype infection, we assessed serum levels of anti-ancestral-S1-IgG, anti-BA.5-receptor binding domain (RBD)-IgG, and anti-XBB.1.16-RBD-IgG using enzyme-linked immunosorbent assay, the neutralizing antibody titer against BA.5 and XBB.1.16 was determined using pseudovirus neutralization assays. Univariate and multivariate binary logistic regression analyses were conducted to identify factors associated with severe infection, the magnitude of specific humoral immunity and susceptibility to XBB variants reinfection. RESULT: Our findings indicate that BA.5-CHDPs with full or booster vaccinations have higher levels of anti-ancestral-S1-IgG than unvaccinated individuals. However, levels of anti-BA.5-RBD-IgG and anti-XBB.1.16-RBD-IgG are much lower. Booster-vaccinated BA.5-CHDPs have significantly higher levels of BA.5 and XBB.1.16 specific antibodies and neutralizing antibodies than unvaccinated patients. Low globulin levels and shorter hemodialysis duration are independent risk factors for XBB reinfection in BA.5-CHDPs. CONCLUSION: Although XBB.1.16 specific neutralizing antibody levels were low in BA.5-CHDPs, these levels cannot predict the risk of reinfection; other potential risk factors need to be investigated in the future.
引用
- Mai W, Shen J, Ma F, et al. Specific humoral immune response and XBB variants re-infection risk of hemodialysis patients after Omicron BA.5 infection in China. Vaccine. 2024. PMID: 39048466. doi:10.1016/j.vaccine.2024.07.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。